Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
Kevin L Winthrop, Séverine Vermeire, Millie D Long, Julian Panés, Siew C Ng, Nicole Kulisek, Rajiv Mundayat, Nervin Lawendy, Ivana Vranic, Irene Modesto, Chinyu Su, Gil Y Melmed, Kevin L Winthrop, Séverine Vermeire, Millie D Long, Julian Panés, Siew C Ng, Nicole Kulisek, Rajiv Mundayat, Nervin Lawendy, Ivana Vranic, Irene Modesto, Chinyu Su, Gil Y Melmed
Abstract
Background: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report herpes zoster (HZ) incidence and risk factors in the tofacitinib UC clinical program (up to 7.8 years).
Methods: Proportions and incidence rates (IRs; unique patients with events/100 patient-years) of HZ were evaluated in 4 cohorts: Induction (phase 2 and 3 induction study data), Maintenance (phase 3 maintenance study data), Overall (data from all phase 2, 3, and open-label, long-term extension studies), and Overall plus interim 6-month phase 3b and 4 data. Herpes zoster risk factors were assessed by Cox regression analysis.
Results: In the Induction and Maintenance Cohorts, IRs for HZ (nonserious and serious) were numerically higher with tofacitinib 10 mg twice daily (BID) vs placebo and tofacitinib 10 vs 5 mg BID, respectively. With all tofacitinib doses (5 or 10 mg BID), IRs (95% confidence intervals) for HZ in the Overall and Overall plus phase 3b/4 Cohorts (total exposure, 2814.4 and 2999.7 patient-years, respectively) were 3.38 (2.73-4.15) and 3.30 (2.67-4.04), respectively. In the Overall plus phase 3b/4 Cohort, >90% of HZ were nonserious; >90% were mild/moderate; >90% resolved without discontinuing tofacitinib; 0.6% of patients had multiple HZ events. Herpes zoster IRs were stable when analyzed by 6-month intervals up to >30 months. Herpes zoster risk factors included older age, lower weight, geographic region, and prior tumor necrosis factor inhibitor (TNFi) failure.
Conclusions: Most HZ events were mild/moderate. Herpes zoster IRs remained stable over 7.8 years of exposure. Older age, lower weight, geographic region, and prior TNFi failure were associated with increased HZ risk.
Clinicaltrials.gov: NCT00787202;NCT01465763;NCT01458951;NCT01458574;NCT01470612;NCT03281304.
Keywords: herpes zoster; tofacitinib; ulcerative colitis.
© 2022 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Figures
References
- Ordás I, Eckmann L, Talamini M, et al. . Ulcerative colitis. Lancet. 2012;380:1606–1619.
- Yun H, Yang S, Chen L, et al. . Risk of herpes zoster in auto-immune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68:2328–2337.
- Ning L, Liu R, Li S, et al. . Increased risk of herpes zoster infection in patients with inflammatory bowel disease: a meta-analysis of cohort studies. Eur J Clin Microbiol Infect Dis. 2020;39:219–227.
- Marra F, Lo E, Kalashnikov V, et al. . Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis. Open Forum Infect Dis. 2016;3:ofw205.
- Gupta G, Lautenbach E, Lewis JD.. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483–1490.
- Long MD, Martin C, Sandler RS, et al. . Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:420–429.
- Sandborn WJ, Ghosh S, Panes J, et al. . Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616–624.
- Sandborn WJ, Su C, Sands BE, et al. . Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
- Colombel J-F, Osterman MT, Thorpe AJ, et al. . maintenance of remission with tofacitinib therapy in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20:116–125.e5.
- Vermeire S, Su C, Lawendy N, et al. . Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial. J Crohns Colitis. 2021;15:1130–1141.
- Winthrop KL, Melmed GY, Vermeire S, et al. . Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24:2258–2265.
- Winthrop KL, Loftus EV, Baumgart DC, et al. . Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates from the ulcerative colitis clinical programme. J Crohns Colitis. 2021;15:914–929.
- Olivera PA, Lasa JS, Bonovas S, et al. . Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158:1554–1573.e12.
- Curtis JR, Xie F, Yun H, et al. . Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1843–1847.
- Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13:320.
- Conaghan PG, Mysler E, Tanaka Y, et al. . Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program. Drug Saf. 2021;44:515–530.
- Winthrop K, Buch MH, Curtis J, et al. . POS0092 Herpes zoster in the filgotinib rheumatoid arthritis program (abstract). Ann Rheum Dis. 2021;80(Suppl 1):255.1255–256 (POS0092).
- Liu GF, Wang J, Liu K, et al. . Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trials. Stat Med. 2006;25:1275–1286.
- Seward JF, Watson BM, Peterson CL, et al. . Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287:606–611.
- US Food and Drug Administration. SHINGRIX: highlights of prescribing information. Accessed February 9, 2022.
- Rahier JF, Magro F, Abreu C, et al. . Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8:443–468.
- Schmader K. Herpes zoster in the elderly: issues related to geriatrics. Clin Infect Dis. 1999;28:736–739.
- Khan N, Patel D, Trivedi C, et al. . Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16:1919–1927.e3.
- Winthrop KL, Yamanaka H, Valdez H, et al. . Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675–2684.
- Winthrop KL, Lebwohl M, Cohen AD, et al. . Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017;77:302–309.
- Cohen SB, Tanaka Y, Mariette X, et al. . Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6:e001395.
- Curran D, Callegaro A, Fahrbach K, et al. . Meta-regression of herpes zoster incidence worldwide. Infect Dis Ther. 2022;11:389–403.
- Forbes HJ, Bhaskaran K, Thomas SL, et al. . Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014;348:g2911.
- Dong J, Chen Y, Tang Y, et al. . Body mass index is associated with inflammatory bowel disease: a systematic review and meta-analysis. PLoS One. 2015;10:e0144872.
- Sandborn WJ, Peyrin-Biroulet L, Sharara AI, et al. . Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status. Clin Gastroenterol Hepatol. 2022;20:591–601.e8.
- Winthrop KL, Harigai M, Genovese MC, et al. . Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020;79:1290–1297.
- Cohen SB, van Vollenhoven RF, Winthrop KL, et al. . Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021;80:304–311.
- Rawlings JS, Rosler KM, Harrison DA.. The JAK/STAT signaling pathway. J Cell Sci. 2004;117:1281–1283.
- Gotthardt D, Trifinopoulos J, Sexl V, et al. . JAK/STAT cytokine signaling at the crossroad of NK cell development and maturation. Front Immunol. 2019;10:1–16.
- Parampalli Yajnanarayana S, Stübig T, Cornez I, et al. . JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015;169:824–833.
- Schönberg K, Rudolph J, Vonnahme M, et al. . JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75:2187–2199.
- Verweij MC, Wellish M, Whitmer T, et al. . Varicella viruses inhibit interferon-stimulated JAK-STAT signaling through multiple mechanisms. PLoS Pathog. 2015;11:e1004901.
- Zerboni L, Sen N, Oliver SL, et al. . Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol. 2014;12:197–210.
- Rubin DT, Modesto I, Vermeire S, et al. . Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. Aliment Pharmacol Ther. 2021;55:302–310.
- Centers for Disease Control and Prevention. Varicella vaccine information for healthcare professionals. Accessed May 14, 2021.
- Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): recombinant zoster vaccine (RZV) and herpes zoster live-attenuated vaccine (ZVL). Accessed May 14, 2021.
- Winthrop KL, Wouters AG, Choy EH, et al. . The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017;69:1969–1977.
- Winthrop KL, Wouters A, Choy EH, et al. . Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. Ann Rheum Dis. 2020;79:669–671.
- US Food and Drug Administration. XELJANZ® (tofacitinib): highlights of prescribing information. Accessed October 26, 2021.
- Centers for Disease Control and Prevention. Zostavax (zoster vaccine live) recommendations. Accessed August 3, 2021.
- Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther. 2016;16:265–271.
- . Shingrix vaccine in patients with moderate to severe ulcerative colitis on tofacitinib. Accessed July 30, 2021.
Source: PubMed